160 related articles for article (PubMed ID: 33280279)
1. Identification of an irreversible PPARγ antagonist with potent anticancer activity.
Peng Y; Zhang Q; Zielinski RM; Howells RD; Welsh WJ
Pharmacol Res Perspect; 2020 Dec; 8(6):e00693. PubMed ID: 33280279
[TBL] [Abstract][Full Text] [Related]
2. Cloxiquine, a traditional antituberculosis agent, suppresses the growth and metastasis of melanoma cells through activation of PPARγ.
Zhang W; Shao W; Dong Z; Zhang S; Liu C; Chen S
Cell Death Dis; 2019 May; 10(6):404. PubMed ID: 31138783
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activating receptors: a new way to treat melanoma?
Schadendorf D
J Invest Dermatol; 2009 May; 129(5):1061-3. PubMed ID: 19369932
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo anti-melanoma effects of ciglitazone.
Botton T; Puissant A; Bahadoran P; Annicotte JS; Fajas L; Ortonne JP; Gozzerino G; Zamoum T; Tartare-Deckert S; Bertolotto C; Ballotti R; Rocchi S
J Invest Dermatol; 2009 May; 129(5):1208-18. PubMed ID: 19177142
[TBL] [Abstract][Full Text] [Related]
5. A computational study to identify the key residues of peroxisome proliferator-activated receptor gamma in the interactions with its antagonists.
Sharifi T; Ghayeb Y
J Biomol Struct Dyn; 2018 May; 36(7):1822-1833. PubMed ID: 28566016
[TBL] [Abstract][Full Text] [Related]
6. Virtual screening and biological evaluation of PPARγ antagonists as potential anti-prostate cancer agents.
Almahmoud S; Elix CC; Jones JO; Hopkins CR; Vennerstrom JL; Zhong HA
Bioorg Med Chem; 2021 Sep; 46():116368. PubMed ID: 34433102
[TBL] [Abstract][Full Text] [Related]
7. Anticancer properties of 4-thiazolidinone derivatives depend on peroxisome proliferator-activated receptor gamma (PPARγ).
Szychowski KA; Leja ML; Kaminskyy DV; Kryshchyshyn AP; Binduga UE; Pinyazhko OR; Lesyk RB; Tobiasz J; Gmiński J
Eur J Med Chem; 2017 Dec; 141():162-168. PubMed ID: 29031063
[TBL] [Abstract][Full Text] [Related]
8. Sulfonylguanidine Derivatives as Potential Antimelanoma Agents.
Baladi T; Hamouda-Tekaya N; Gonçalves LCP; Rocchi S; Ronco C; Benhida R
ChemMedChem; 2020 Jul; 15(13):1113-1117. PubMed ID: 32347004
[TBL] [Abstract][Full Text] [Related]
9. 3,3',4,4',5,5'-hexahydroxystilbene impairs melanoma progression in a metastatic mouse model.
Paulitschke V; Schicher N; Szekeres T; Jäger W; Elbling L; Riemer AB; Scheiner O; Trimurtulu G; Venkateswarlu S; Mikula M; Swoboda A; Fiebiger E; Gerner C; Pehamberger H; Kunstfeld R
J Invest Dermatol; 2010 Jun; 130(6):1668-79. PubMed ID: 19956188
[TBL] [Abstract][Full Text] [Related]
10. A promising in silico protocol to develop novel PPARγ antagonists as potential anticancer agents: Design, synthesis and experimental validation via PPARγ protein activity and competitive binding assay.
Sivamani Y; Shanmugarajan D; Durai Ananda Kumar T; Faizan S; Channappa B; Naishima NL; Prashantha Kumar BR
Comput Biol Chem; 2021 Dec; 95():107600. PubMed ID: 34794076
[TBL] [Abstract][Full Text] [Related]
11. EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma.
Capone E; Lamolinara A; D'Agostino D; Rossi C; De Laurenzi V; Iezzi M; Iacobelli S; Sala G
J Control Release; 2018 May; 277():48-56. PubMed ID: 29550398
[TBL] [Abstract][Full Text] [Related]
12. Cell-targeted c(AmpRGD)-sunitinib molecular conjugates impair tumor growth of melanoma.
Bianchini F; Portioli E; Ferlenghi F; Vacondio F; Andreucci E; Biagioni A; Ruzzolini J; Peppicelli S; Lulli M; Calorini L; Battistini L; Zanardi F; Sartori A
Cancer Lett; 2019 Apr; 446():25-37. PubMed ID: 30639534
[TBL] [Abstract][Full Text] [Related]
13. Anti-proliferative effect of peroxisome proliferator-activated receptor gamma agonists on human malignant melanoma cells in vitro.
Freudlsperger C; Moll I; Schumacher U; Thies A
Anticancer Drugs; 2006 Mar; 17(3):325-32. PubMed ID: 16520661
[TBL] [Abstract][Full Text] [Related]
14. Anticancer Activity of Two Novel Hydroxylated Biphenyl Compounds toward Malignant Melanoma Cells.
Pisano M; Dettori MA; Fabbri D; Delogu G; Palmieri G; Rozzo C
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073232
[TBL] [Abstract][Full Text] [Related]
15. PPARgamma inhibitors reduce tubulin protein levels by a PPARgamma, PPARdelta and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells.
Schaefer KL; Takahashi H; Morales VM; Harris G; Barton S; Osawa E; Nakajima A; Saubermann LJ
Int J Cancer; 2007 Feb; 120(3):702-13. PubMed ID: 17096328
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic effect of a family of peroxisome proliferator-activated receptor antagonists in colorectal and pancreatic cancer cell lines.
Ammazzalorso A; De Lellis L; Florio R; Bruno I; De Filippis B; Fantacuzzi M; Giampietro L; Maccallini C; Perconti S; Verginelli F; Cama A; Amoroso R
Chem Biol Drug Des; 2017 Nov; 90(5):1029-1035. PubMed ID: 28544586
[TBL] [Abstract][Full Text] [Related]
17. PPAR γ agonist, pioglitazone, suppresses melanoma cancer in mice by inhibiting TLR4 signaling.
Dana N; Vaseghi G; Haghjooy Javanmard S
J Pharm Pharm Sci; 2019; 22(1):418-423. PubMed ID: 31509504
[TBL] [Abstract][Full Text] [Related]
18. Potent USP10/13 antagonist spautin-1 suppresses melanoma growth via ROS-mediated DNA damage and exhibits synergy with cisplatin.
Guo J; Zhang J; Liang L; Liu N; Qi M; Zhao S; Su J; Liu J; Peng C; Chen X; Liu H
J Cell Mol Med; 2020 Apr; 24(7):4324-4340. PubMed ID: 32129945
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of the antimetastatic efficacy of Pentoxifylline on A375 human melanoma cell line.
Kamran MZ; Gude RP
Biomed Pharmacother; 2012 Dec; 66(8):617-26. PubMed ID: 23089470
[TBL] [Abstract][Full Text] [Related]
20. JTP-426467 acts as a selective antagonist for peroxisome proliferator-activated receptor gamma in vitro and in vivo.
Nishiu J; Ito M; Ishida Y; Kakutani M; Shibata T; Matsushita M; Shindo M
Diabetes Obes Metab; 2006 Sep; 8(5):508-16. PubMed ID: 16918585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
